Yayın: Bortezomib and extramedullary disease in multiple myeloma: The shine and dark side of the moon
| dc.contributor.buuauthor | Ali, Rıdvan | |
| dc.contributor.buuauthor | Özkalemkaş, Fahir | |
| dc.contributor.buuauthor | Özkan, Atilla | |
| dc.contributor.buuauthor | Özkocaman, Vildan | |
| dc.contributor.buuauthor | Özçelik, Tülay | |
| dc.contributor.buuauthor | Ozan, Ülkü | |
| dc.contributor.department | Tıp Fakültesi | |
| dc.contributor.department | Tıp Fakültesi | |
| dc.contributor.department | Hematoloji Ana Bilim Dalı | |
| dc.contributor.department | Radyasyon Onkoloji Ana Bilim Dalı | |
| dc.contributor.researcherid | AAG-8495-2021 | |
| dc.contributor.researcherid | AAH-1854-2021 | |
| dc.contributor.scopusid | 7201813027 | |
| dc.contributor.scopusid | 6601912387 | |
| dc.contributor.scopusid | 9250698600 | |
| dc.contributor.scopusid | 6603145040 | |
| dc.contributor.scopusid | 7005424333 | |
| dc.contributor.scopusid | 6507254632 | |
| dc.contributor.scopusid | 8843050600 | |
| dc.contributor.scopusid | 6602797853 | |
| dc.date.accessioned | 2022-10-06T07:43:36Z | |
| dc.date.available | 2022-10-06T07:43:36Z | |
| dc.date.issued | 2007-08 | |
| dc.identifier.citation | Ali, R. vd. (2007). "Bortezomib and extramedullary disease in multiple myeloma: The shine and dark side of the moon". Lekukemia Research, 31(8), 1153-1155. | |
| dc.identifier.doi | 10.1016/j.leukres.2006.07.017 | |
| dc.identifier.endpage | 1153 | |
| dc.identifier.issn | 0145-2126 | |
| dc.identifier.issn | 1873-5835 | |
| dc.identifier.issue | 8 | |
| dc.identifier.pubmed | 16945413 | |
| dc.identifier.scopus | 2-s2.0-34249871670 | |
| dc.identifier.uri | https://doi.org/10.1016/j.leukres.2006.07.017 | |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0145212606002700 | |
| dc.identifier.uri | http://hdl.handle.net/11452/28992 | |
| dc.identifier.volume | 31 | |
| dc.identifier.wos | 000248062000019 | |
| dc.indexed.scopus | Scopus | |
| dc.indexed.wos | SCIE | |
| dc.language.iso | en | |
| dc.publisher | Pergamon-Elsevier Science | |
| dc.relation.journal | Leukemia Research | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
| dc.relation.tubitak | 1155 | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | Progression | |
| dc.subject | Plasmacytoma | |
| dc.subject | Therapy | |
| dc.subject.emtree | Disease course | |
| dc.subject.emtree | Aged | |
| dc.subject.emtree | Allogeneic stem cell transplantation | |
| dc.subject.emtree | Autologous stem cell transplantation | |
| dc.subject.emtree | Backache | |
| dc.subject.emtree | Bone marrow biopsy | |
| dc.subject.emtree | Cancer relapse | |
| dc.subject.emtree | Cancer staging | |
| dc.subject.emtree | Case report | |
| dc.subject.emtree | Combination chemotherapy | |
| dc.subject.emtree | Computer assisted tomography | |
| dc.subject.emtree | Diarrhea | |
| dc.subject.emtree | Female | |
| dc.subject.emtree | Antineoplastic agent | |
| dc.subject.emtree | Histopathology | |
| dc.subject.emtree | Prednisone | |
| dc.subject.emtree | Human | |
| dc.subject.emtree | Vincristine | |
| dc.subject.emtree | Boronic acid derivative | |
| dc.subject.emtree | Bortezomib | |
| dc.subject.emtree | Human tissue | |
| dc.subject.emtree | Pyrazine derivative | |
| dc.subject.emtree | Letter | |
| dc.subject.emtree | Alpha2b interferon | |
| dc.subject.emtree | Plasmacytoma | |
| dc.subject.emtree | Bortezomib | |
| dc.subject.emtree | Multiple cycle treatment | |
| dc.subject.emtree | Multiple myeloma | |
| dc.subject.emtree | Neuropathy | |
| dc.subject.emtree | Neutropenia | |
| dc.subject.emtree | Pathology | |
| dc.subject.emtree | Priority journal | |
| dc.subject.emtree | Dexamethasone | |
| dc.subject.emtree | Pneumonia | |
| dc.subject.emtree | Plasmacytoma | |
| dc.subject.emtree | Doxorubicin | |
| dc.subject.emtree | Melphalan | |
| dc.subject.emtree | Radiodiagnosis | |
| dc.subject.emtree | Remission | |
| dc.subject.emtree | Thrombocytopenia | |
| dc.subject.emtree | Treatment outcome | |
| dc.subject.emtree | Multiple myeloma | |
| dc.subject.mesh | Plasmacytoma | |
| dc.subject.mesh | Aged | |
| dc.subject.mesh | Antineoplastic agents | |
| dc.subject.mesh | Boronic acids | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Multiple myeloma | |
| dc.subject.mesh | Pyrazines | |
| dc.subject.mesh | Treatment outcome | |
| dc.subject.scopus | Plasmacytoma; Multiple Myeloma; Pleura Effusion | |
| dc.subject.wos | Oncology | |
| dc.subject.wos | Hematology | |
| dc.title | Bortezomib and extramedullary disease in multiple myeloma: The shine and dark side of the moon | |
| dc.type | Letter | |
| dc.wos.quartile | Q2 (Hematology) | |
| dc.wos.quartile | Q3 (Oncology) | |
| dc.wos.quartile | Q2 | |
| dc.wos.quartile | Q3 | |
| dspace.entity.type | Publication | |
| local.contributor.department | Tıp Fakültesi/Hematoloji Ana Bilim Dalı | |
| local.contributor.department | Tıp Fakültesi/Radyasyon Onkoloji Ana Bilim Dalı | |
| local.indexed.at | PubMed | |
| local.indexed.at | WOS | |
| local.indexed.at | Scopus |
Dosyalar
Lisanslı seri
1 - 1 / 1
